• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阐明腺嘌呤 A1 受体变构调节剂的作用模式。

Delineating the mode of action of adenosine A1 receptor allosteric modulators.

机构信息

Drug Discovery Biology & Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.

出版信息

Mol Pharmacol. 2010 Sep;78(3):444-55. doi: 10.1124/mol.110.064568. Epub 2010 Jun 14.

DOI:10.1124/mol.110.064568
PMID:20547736
Abstract

Despite the identification of 2-amino-3-benzoylthiophenes (2A3BTs) as the first example of small-molecule allosteric potentiators of agonist function at a G protein-coupled receptor (GPCR)-the adenosine A(1) receptor-their mechanism of action is still not fully understood. We now report the mechanistic basis for the complex behaviors noted for 2A3BTs at A(1) receptors. Using a combination of membrane-based and intact-cell radioligand binding, multiple signaling assays, and a native tissue bioassay, we found that the allosteric interaction between 2A3BTs and the agonists 2-chloro-N(6)-[(3)H]cyclopentyladenosine or (-)-N(6)-(2-phenylisopropyl)adenosine (R-PIA) or the antagonist [(3)H]8-cyclopentyl-1,3-dipropylxanthine is consistent with a ternary complex model involving recognition of a single extracellular allosteric site. However, when allowed access to the intracellular milieu, 2A3BTs have a secondary action as direct G protein inhibitors; this latter property is receptor-independent as it is observed in nontransfected cells and also after stimulation of another GPCR. In addition, we found that 2A3BTs can signal as allosteric agonists in their own right but show bias toward certain pathways relative to the orthosteric agonist, R-PIA. These results indicate that 2A3BTs have a dual mode of action when interacting with the A(1) receptor and that they can engender novel functional selectivity in A(1) signaling. These mechanisms need to be factored into allosteric ligand structure-activity studies.

摘要

尽管已经确定 2-氨基-3-苯甲酰噻吩(2A3BTs)是第一个小分子变构激动剂,可增强 G 蛋白偶联受体(GPCR)-腺苷 A(1)受体激动剂的功能,但它们的作用机制仍不完全清楚。我们现在报告了 2A3BTs 在 A(1)受体上的复杂行为的机制基础。使用膜结合和完整细胞放射性配体结合、多种信号转导测定和天然组织生物测定的组合,我们发现 2A3BTs 与激动剂 2-氯-N(6)-[(3)H]环戊基腺苷或(-)-N(6)-(2-苯基异丙基)腺苷(R-PIA)或拮抗剂 [(3)H]8-环戊基-1,3-二丙基黄嘌呤之间的变构相互作用与涉及识别单个细胞外变构位点的三元复合物模型一致。然而,当允许进入细胞内环境时,2A3BTs 具有作为直接 G 蛋白抑制剂的次要作用;这种后一种性质是受体非依赖性的,因为它在未转染的细胞中观察到,并且在另一种 GPCR 刺激后也观察到。此外,我们发现 2A3BTs 可以自行作为变构激动剂发挥信号作用,但相对于正构激动剂 R-PIA,它们对某些途径表现出偏向性。这些结果表明,2A3BTs 在与 A(1)受体相互作用时具有双重作用模式,并且它们可以在 A(1)信号传导中产生新的功能选择性。这些机制需要在变构配体结构活性研究中加以考虑。

相似文献

1
Delineating the mode of action of adenosine A1 receptor allosteric modulators.阐明腺嘌呤 A1 受体变构调节剂的作用模式。
Mol Pharmacol. 2010 Sep;78(3):444-55. doi: 10.1124/mol.110.064568. Epub 2010 Jun 14.
2
Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor.新型 2-氨基-3-苯甲酰基噻吩衍生物的合成与表征作为腺苷 A(1)受体的别构激动剂和调节剂。
J Med Chem. 2012 Mar 8;55(5):2367-75. doi: 10.1021/jm201600e. Epub 2012 Feb 17.
3
Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist.新型非腺苷类激动剂LUF5831对野生型和突变型(T277A)腺苷A1受体的变构调节、热力学及结合作用
Br J Pharmacol. 2006 Mar;147(5):533-41. doi: 10.1038/sj.bjp.0706655.
4
Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity.腺苷A1受体的第二个细胞外环在变构调节剂结合、信号传导和协同性中的作用
Mol Pharmacol. 2016 Dec;90(6):715-725. doi: 10.1124/mol.116.105015. Epub 2016 Sep 28.
5
The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.变构增强剂PD81,723增强了嵌合A1/A2A腺苷受体与Gs的偶联。
Biochem J. 2006 May 15;396(1):139-46. doi: 10.1042/BJ20051422.
6
Allosteric modulation of adenosine A1 and cannabinoid 1 receptor signaling by G-peptides.G 肽对腺苷 A1 和大麻素 1 受体信号的变构调节。
Pharmacol Res Perspect. 2020 Dec;8(6):e00673. doi: 10.1002/prp2.673.
7
Allosteric modulation and constitutive activity of fusion proteins between the adenosine A1 receptor and different 351Cys-mutated Gi alpha-subunits.腺苷A1受体与不同351位半胱氨酸突变的Giα亚基之间融合蛋白的变构调节和组成性活性。
Eur J Pharmacol. 2004 Sep 19;499(1-2):91-8. doi: 10.1016/j.ejphar.2004.07.108.
8
Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes.2-氨基-3-苯甲酰基噻吩对腺苷A1受体结合及功能的变构增强作用
Mol Pharmacol. 1990 Dec;38(6):939-49.
9
Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors.阿米洛利类似物对激动剂和拮抗剂在A(1)和A(3)腺苷受体上结合的差异变构调节作用。
Biochem Pharmacol. 2003 Feb 15;65(4):525-34. doi: 10.1016/s0006-2952(02)01556-3.
10
Comparison of effects of MgCl2 and Gpp(NH)p on antagonist and agonist radioligand binding to adenosine A1 receptors.MgCl₂ 和 Gpp(NH)p 对拮抗剂和激动剂放射性配体与腺苷 A1 受体结合的影响比较。
Acta Pharmacol Sin. 2003 Aug;24(8):729-40.

引用本文的文献

1
Biased agonism of G protein-coupled receptors as a novel strategy for osteoarthritis therapy.G蛋白偶联受体的偏向性激动作用作为骨关节炎治疗的新策略。
Bone Res. 2025 May 12;13(1):52. doi: 10.1038/s41413-025-00435-y.
2
Small molecule allosteric modulation of the adenosine A receptor.小分子变构调节腺苷 A 受体。
Front Endocrinol (Lausanne). 2023 Jun 26;14:1184360. doi: 10.3389/fendo.2023.1184360. eCollection 2023.
3
Adenosine receptors: Emerging non-opioids targets for pain medications.腺苷受体:疼痛药物新出现的非阿片类靶点。
Neurobiol Pain. 2022 Mar 25;11:100087. doi: 10.1016/j.ynpai.2022.100087. eCollection 2022 Jan-Jul.
4
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.国际基础和临床药理学联合会。CXII:腺苷受体:进一步更新。
Pharmacol Rev. 2022 Apr;74(2):340-372. doi: 10.1124/pharmrev.121.000445.
5
The effect of two selective A -receptor agonists and the bitopic ligand VCP746 on heart rate and regional vascular conductance in conscious rats.两种选择性 A-受体激动剂和双位配体 VCP746 对清醒大鼠心率和局部血管传导率的影响。
Br J Pharmacol. 2020 Jan;177(2):346-359. doi: 10.1111/bph.14870. Epub 2020 Jan 1.
6
Probe dependence of allosteric enhancers on the binding affinity of adenosine A -receptor agonists at rat and human A -receptors measured using NanoBRET.使用 NanoBRET 测量大鼠和人 A 受体上腺苷 A -受体激动剂的结合亲和力,研究变构增强剂对探针的依赖性。
Br J Pharmacol. 2019 Apr;176(7):864-878. doi: 10.1111/bph.14575. Epub 2019 Mar 6.
7
G Protein-coupled Receptor Biased Agonism.G蛋白偶联受体偏向性激动作用
J Cardiovasc Pharmacol. 2016 Mar;67(3):193-202. doi: 10.1097/FJC.0000000000000356.
8
Concentration-Dependent Dual Mode of Zn Action at Serotonin 5-HT1A Receptors: In Vitro and In Vivo Studies.锌离子对5-羟色胺5-HT1A受体作用的浓度依赖性双重模式:体外和体内研究
Mol Neurobiol. 2016 Dec;53(10):6869-6881. doi: 10.1007/s12035-015-9586-3. Epub 2015 Dec 12.
9
A common molecular motif characterizes extracellular allosteric enhancers of GPCR aminergic receptors and suggests enhancer mechanism of action.一种常见的分子基序是GPCR胺能受体细胞外变构增强剂的特征,并提示了增强剂的作用机制。
Curr Med Chem. 2014;21(32):3673-86. doi: 10.2174/0929867321666140826120604.
10
Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.通过合理设计双位腺嘌呤受体激动剂,将靶效应与不良反应分离。
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4614-9. doi: 10.1073/pnas.1320962111. Epub 2014 Mar 11.